Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
Twice-daily tenofovir alafenamide plus rifampicin provided similar exposures to once-daily TAF in a pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.
Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016.
In countries such as South Africa with a high burden of TB and HIV, vitamin D could be an extremely effective and cheap weapon to include in the arsenal against the diseases.
With buildings leveled by arson and systematic neglect, its population crammed into debilitated and overcrowded housing without access to basic public safety and public health services, the inescapable poverty of the Bronx provided fertile ground for...